INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Solving the Challenges of Patient Recruitment

John Clarke, MSc

John Clarke, MSc

Associate Director, Patient Recruitment

Author picture

 

PharmaTimes, the UK’s leading pharmaceutical magazine, John Clarke, Associate Director in Patient Recruitment at Indero, explores the transformative trends reshaping the pharmaceutical industry. This issue explores:

  • The increasing role of self-care in national health, the critical importance of adherence in modern medicine, and the innovative dimensions emerging within the sector.
  • With insightful articles on treatments, collaborations, and cutting-edge innovations, this edition is a must-read for anyone interested in the future of healthcare.

For a deeper dive into these topics, follow the link to read the full article here:

  Read More

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.
Talk to us

Jeff Smith

Chef de la direction
Linkedin

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.
LEARN MORE >